Meaningful Insights Biotech Analytics (MiBA), an innovative healthcare AI technology company specializing in oncology data intelligence, today announced a strategic partnership with Oncology Consultants (OC), a leading provider of comprehensive cancer care in the Houston area. This collaboration aims to enhance patient outcomes through AI-powered analytics, real-time insights and expanded clinical trial access, empowering OC’s physicians with cutting-edge tools for personalized, data-driven care.
MiBA delivers meaningful insights by combining advanced AI, data science, and oncology expertise to transform real-world oncology data into actionable intelligence. Its network spans more than 41 practices, more than 300 community providers, and more than 700,000 patient records, offering superior data quality via nightly updates and AI technologies such as natural language processing and large language models. For OC, this optimizes treatment pathways, biomarker testing and operational efficiencies for precision medicine, enabling accelerated research, personalized plans and real-world data projects while closing the feedback loop among physicians, patients and industry partners.
Highlighting MiBA’s breakthrough technologies, the partnership leverages AI-powered analytics that synthesize multimodal data to uncover hidden patterns with greater than 0.9 precision and recall. Innovations such as real-time intelligence with daily updates, de-identified data sets and advanced real-world evidence integrate with OC’s world-class medicine—expert physicians, state-of-the-art treatments and personalized care. Together, they deliver faster trial matching, enhanced biomarker optimization, accelerated research and drug development, improved market access and better cancer outcomes by bridging data intelligence with clinical expertise.
A key focus is expanding clinical trial opportunities for OC’s patients via MiBA’s Trials™ platform, featuring AI for feasibility, site selection, patient identification and monitoring. This streamlines enrollment, matches patients to cutting-edge studies efficiently, bridges trial access gaps and enables more Houston patients to join innovative therapies that advance research and survival rates.
“Our partnership with Oncology Consultants marks a major advance in integrating real-time data intelligence into community oncology,” said Mark Moch, managing partner at MiBA. “By empowering OC’s team with precision insights, biomarker optimization and accelerated trial matching, we’re creating a collaborative ecosystem for patient-centered innovation. Together, we’ll unlock oncology data patterns to drive better outcomes and fight cancer.”
“We are thrilled to partner with MiBA for transformative AI-driven insights,” said Dr. Luis T. Campos, president of Oncology Consultants. “This collaboration enhances our state-of-the-art, personalized treatments and expands clinical trial capabilities, allowing patients to access the latest oncology advancements across southeast Texas. By leveraging MiBA’s AI-powered analytics through its Trials™ platform, we are improving how we identify and enroll patients in clinical trials, helping more individuals participate in innovative studies close to home while supporting more informed, data-driven care.”
This partnership builds on MiBA’s proven collaborations with industry leaders and strengthens its role in advancing oncology innovation.